β-Galactosidase-activated theranostic for hepatic carcinoma therapy and imaging
Mrinmoy Maiti, Kai Kikuchi, K. K. Athul, Amandeep Kaur, Sankarprasad Bhuniya
Abstract
A β-galactosidase activatable fluorescent turn-on theranostic Gal-CGem exhibits gemcitabine release specifically in β-galactosidase overexpressing hepatic carcinoma cells. The cytotoxicity of Gal-CGem in cancer cells is achieved through the apoptotic cell death pathway. Overall, Gal-CGem is a new frontline prodrug in cancer therapy that has provided antineoplastic information through fluorescence imaging.
Topics & Concepts
GemcitabineCytotoxicityProdrugCancer researchApoptosisLiver cancerPhotodynamic therapyCancer cellChemistryCancerMedicineInternal medicineBiochemistryIn vitroHepatocellular carcinomaOrganic chemistryNanoplatforms for cancer theranosticsNanoparticle-Based Drug DeliveryGraphene and Nanomaterials Applications